[1] |
XIE Rui, GENG Zihan, BAO Lei, ZHAO Ronghua, LI Shuran, SUN Qiyue, WANG Xinwei, ZHANG Jingsheng, CUI Xiaolan, GUO Shanshan, SUN Jing.
Research Progress in Pharmacological Actions, Mechanisms, Structural Modifications and Targeted Formulations of Ribavirin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 950-955.
|
[2] |
LIU Ming, ZHENG Li, ZHANG Weina, SUN Xuelin, TIAN Jinhui, ZHAO Yan.
Research Progress in Biological Activity and Mechanisms of Pachymic Acid
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 826-830.
|
[3] |
YE Ling, LIU Xiaoying, DANG Xuefei, LI Xuelian, LI Gang.
Research Progress in Drugs for Brain Metastases from Advanced Breast Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 714-720.
|
[4] |
BAI Xue, CHEN Yafei, TANG Tian, LIU Zhejun, WANG Guoyu, TAN Tianyang.
Progress in Clinical and Pharmacological Research of Angong Niuhuang Pills
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 349-356.
|
[5] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
[6] |
HU Xiaozhen, MA Lina, HE Ting, GU Yuanyuan, ZHAO Wei, ZHENG Changhui, YE Zuguang, CAO Junling.
Literature research on ancient and modern literature of Dichroae Radix and Shu lacquer
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 587-593.
|
[7] |
HUANG Huanjun, MAI Jiaheng, ZHANG Yunhui, GUO Chenchen, LIANG Weiting.
Adverse drug reaction induced by antineoplastic drugs in a cancer hospital: an analysis of 613 cases
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 324-328.
|
[8] |
LIU Sujie, YAN Jiahe, RUAN Jiaxin, WANG Chen, WANG Xiaofan, LIU Shumin, BAI Xue.
Research Progress in Regulation of Wnt/β-Catenin Signaling Pathway by TCM in the Treatment of Ischemic Stroke
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1388-1392.
|
[9] |
BAI Xue, CHEN Yafei, TANG Tian, LIU Zhejun, TAN Tianyang, LIU Zhenquan.
Research Progress on the Potential Therapeutic Effect of Bushen Shengjing Prescription on Oligoasthenozoospermia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1243-1249.
|
[10] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[11] |
YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling.
Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
|
[12] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|
[13] |
DONG Shoutang, ZHANG Xuqiang, WANG huaibin, CHAI Lianzhou, YANG Hongqin, HU Yan.
Antioxidant effect of Dendrobium devonianum polysaccharides on oxidative damage mice induced by D-galactose
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1078-1081.
|
[14] |
WANG Xiao, HE Xuan, DAI Huizhen, LI Xin, HAN Feng.
Market Competition Trends of Innovative Anti-tumor Drugs in Nanjing Based on Terminal Data
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 731-736.
|
[15] |
WANG Yanchun, WANG Jianqiang.
Research Progress in Clinical Application of Shuganning Injection
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 543-547.
|